4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 10▼ RSI OverboughtRSI 72.3, above 70, stock may be overbought
Jul 9▼ RSI OverboughtRSI 70.6, above 70, stock may be overbought
About Covista Inc.
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Valued at $4.02B, CVSA is a mid-cap name in its sector.
Premium feature
News & analytics is part of Premium.
Every headline runs through our finance-grade sentiment engine, so you see the mood of the market on each ticker before you read a single article. Plus the full analyst consensus and target-price upside, refreshed daily.
Per-headline sentiment, scored by a finance-tuned model
See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.
The company holds $147.0M in cash, though total debt stands at $736.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $274.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 17.8% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.38B (2022) to $1.79B (2025), reflecting a 29% increase over the period.
The relatively low beta of 0.62 suggests CVSA is a less volatile holding compared to the broader index. Covista Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing CVSA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.